EUCTR2006-002772-17-FR进行中（未招募）1 期
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A Phase III study
European Organisation for Research and Treatment of Cancer0 个研究点目标入组 86 人开始时间: 2009年4月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 86
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Patients with clinical stage cT1-2-3aN0M0 prostate cancer (UICC TNM 2002, see Appendix D) clinically assessed after a preoperative work-up including physical examination, chest X-ray, bone scan, CT scan or MRI of the entire pelvis and abdomen.
- •- Pre-operative PSA = 5 x upper limit of normal (ULN).
- •- Presenting after radical prostatectomy (all techniques allowed: retropubic, laparoscopic or perineal) with (see pathological assessment protocol in Appendix E):
- •*Gleason sum 5-10
- •*Pathologic stage pT2R1 (positive surgical margins with at least a tumor trans-section higher than 2 mm) or pT3a-b (irrespective of margin status)
- •*Negative lymph node (LN) status (pN0) by LN sampling or LN dissection. Unknown
- •pathological LN status (pNx, i.e. omission of LN sampling or LN dissection) is not allowed except for patients classified as cT = cT1c with baseline PSA = 10ng/ml and Gleason score < 7 and positive core biopsies < 50%, provided the total number of random biopsies is at least 12
- •*Undetectable post-operative PSA (PSA is below the detection level of the laboratory) within 3 months of surgery
- •- Age = 80 years.
- •- WHO performance status 0-1.
- •- Normal organ functions as shown by all of the following (measured within 2 weeks prior to randomization):
- •*hemoglobin = 110 g/l
- •*WBC =3 x 109/l
- •*platelet count = 100 x 109/l
- •- External irradiation must be planned to start within 4 months after surgery. Randomization should take place as shortly as possible before the start of the treatment and a maximum of 3 months after surgery, and the patient must be fully continent.
- •- Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
- •Patients can be randomized in this trial only once.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- prior pelvic irradiation.
- •- prior bilateral orchiectomy.
- •- prior chemotherapy within the 5 years prior to randomization.
- •- prior hormonal treatment except neo-adjuvant treatment lasting = 3 months.
- •- other malignancy except adequately treated basal cell carcinoma of the skin or other malignancy from which the patient has been disease free for at least 5 years.
- •- psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial.
研究者
相似试验
进行中（未招募）
不适用
Radioterapia externa postoperatoria combinada con tratamiento hormonal adyuvante y concomitante frente a la radioterapia externa postoperatoria como tratamiento único en el carcinoma de próstata estadio pT3a-b R0-1 N0M0 / pT2R1 N0M0 y con puntuación de Gleason 5-10. Estudio fase III.(Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A Phase III study)n carcinoma de próstata estadio pT3a-b R0-1 N0M0 / pT2R1 N0M0 y con puntuación de Gleason 5-10.(Prostatic carcinoma with pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10)MedDRA version: 9.1Level: LLTClassification code 10036955Term: Prostatic carcinomaEUCTR2006-002772-17-ESEuropean Organisation for Research and Treatment of Cancer600
招募中
3 期
Postoperative radiotherapy (PORT) for pathological N2 non-small cell lung cancer with adjuvant chemotherapy: a randomized phase III trial (JCOG1916, J-PORT)pathological N2 non-small cell lung cancerJPRN-UMIN000042905Japan Clinical Oncology Group (JCOG)330
尚未招募
2 期
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a Phase-II and observation study (EORTC 22042-26042)NL-OMON32223EORTC30
已完成
4 期
Effectiveness of postoperative radiotherapy in patients with oral or oropharyngeal squamous cell carcinoma and histologically confirmed single ipsilateral lymphnode metastasis (pN1)head-neck cancer metastasis1002747610019190oral cancerNL-OMON30589Academisch Medisch Centrum12
招募中
2 期
A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancerinoperable or recurrent PD-L1 positive triple negative breast cancerJPRN-jRCTs021210010Suzuki Yoshiyuki20